The KPCXM18 not checked

Kunming Pharmaceuticals, Inc.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
None yet
 
Trials
1 active
2 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“Intravenous infusion of 100 mg twice daily at intervals of 12±2 hours for 12±2 days.”In the company’s words, NCT07279493 on ClinicalTrials.gov
Tested for
Acute Ischemic Stroke
Main trialPhase 2
“This study is a multicenter, randomized, double-blind, parallel, placebo-controlled trial design to evaluate the efficacy and safety of the KPCXM18 injection at different doses for the treatment of acute ischemic stroke.”In the company’s words, NCT07279493 on ClinicalTrials.gov

Other drugs for Acute Ischemic Stroke

All 45 drugs for Acute Ischemic Stroke

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 2Recruiting 18 Oct 2026 Efficacy and Safety of the KPCXM18 Injection in Patients With Acute Ischemic Stroke
Phase 2Unknown 1 May 2024 Study of the KPCXM18 Injection for Treatment of Acute Ischemic Stroke
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow The KPCXM18

Following is part of Solo: you see every change to The KPCXM18 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in